Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

James Ashton: AGMs season can still put trouble on agenda

 

James Ashton
Saturday 27 April 2013 00:17 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Like the first swallow of summer, Barclays’ shareholder meeting this week signified the beginning of the AGM season. But if signs of summer are upon us, what happened to this year’s shareholder spring?

By this time last year, the first big corporate scalp had been claimed. David Brennan announced his exit from AstraZeneca on 26 April, followed by Sly Bailey from the newspaper publisher Trinity Mirror a week later and Andrew Moss, the chief of insurance giant Aviva, five days after that.

So far, it’s all quiet on the Western Front. It is, of course, early. With all those March year-end companies, the AGM season stretches through until July. And just because bosses bore the brunt of shareholders’ ire last year, it doesn’t mean they will again. But I very much doubt that investors and executives have reached a happy accord.

Perhaps in anticipation of a row, companies get so skittish. A special mention should go to AstraZeneca for making my colleague Lucy Tobin so unwelcome at its AGM on Thursday. Maybe only when the shrinking drug maker has turned around its dolorous performance will it happily throw open its doors.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in